All In MedTech

Device Trial Radar · NCT04808323

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Jun 17, 2021

Primary completion

Apr 14, 2027

Study completion Jan 20, 2029

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 22, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, phase I design.

Conditions

  • Rectal Adenocarcinoma

Interventions

  • CapecitabineDrug

    825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.

  • Initial Dose of Radiation before Dose EscalationDevice

    50 Gy over 25 frac.

  • Cohort A: Dose Escalation RadiationDevice

    Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.

  • Cohort B: Dose Escalation RadiationDevice

    Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.

  • Cohort C: Dose Escalation RadiationDevice

    Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.

  • FOLFOXDrug

    After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects in Cohort A with serious adverse events during radiation.Time frame: Up to 11.5-week period
  2. The number of subjects in Cohort B with serious adverse events during radiation.Time frame: Up to 11.5-week period
  3. The number of subjects in Cohort C with serious adverse events during radiation.Time frame: Up to a 12.1-week period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.